The combination of aztreonam and cefozopran against Stenotrophomonas maltophilia.
Aztreonam is suited for combination chemotherapy because it could be a potent Beta-lactamase inhibitor. We designed a study to show the inhibitory activity of aztreonam, using Stenotrophomonas maltophilia, which produces both carbapenemase L1 and penicillinase L2. Aztreonam showed considerable synergy with cefpirome and contributed to a decrease in minimum inhibitory concentrations of cefozopran. In further examinations, the mean viable bacterial counts in cultures treated with aztreonam-cefozopran were 1 log lower than those in cultures treated with cefozopran alone. These results confirm that inhibition of penicillinase L2 occurred. We hope that a combination chemotherapy using aztreonam and cefozopran will be used to prevent the emergence of penicillinase-producers.
Department of Microbiology, Tottori University Faculty of Medicine, Yonago, Japa. dkataoka@grape.med.tottori-u.ac.jp
Daisuke
D
Kataoka
Yoshinori
Y
Tanaka
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001398:Aztreonam / Q000494:pharmacology*; D002511:Cephalosporins / Q000494:pharmacology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*; D065093:beta-Lactamase Inhibitors; D000097586:Cefozopran
D000900:Anti-Bacterial Agents; D001398:Aztreonam; D002511:Cephalosporins; D065093:beta-Lactamase Inhibitors; D000097586:Cefozopran